Gilead Sciences Inc (GILD) 91.86 $GILD
Gilead Sciences (GILD) Stock Lifted by Leerink's Confidence
at The Street - Thu Mar 31, 2:08PM CDT
It appears that Gilead Sciences (GILD) is continuing to dominate in hepatitis C, Leerink analysts said.
GILD: 91.86 (-0.11)
Pfizer Tops List of Best Biopharmaceutical Brands
at The Street - Thu Mar 31, 1:09PM CDT
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top 10 biopharmaceutical brands.
JNJ: 108.20 (-0.78), GILD: 91.86 (-0.11), AZN: 28.16 (-0.16), MRK: 52.91 (-0.31), PFE: 29.64 (-0.43), AMGN: 149.93 (+0.45), GSK: 40.55 (-0.15), NVS: 72.44 (-0.11)
5 Large Cap Stocks with P/Es Below 15: A Must Buy?
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 8:37AM CDT
Large Cap Stocks with P/Es below 15.
ZBH: 106.63 (-0.07), GILD: 91.86 (-0.11), XRX: 11.16 (+0.33), KORS: 56.96 (+0.09), HPE: 17.73 (-0.16)
Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection
BusinessWire - Thu Mar 31, 1:02AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has submitted a New Drug Application (NDA) to Japan's Pharmaceutical and Medical Devices Agency (PMDA) for tenofovir alafenamide (TAF) 25 mg, an investigational once-daily treatment for adults with chronic hepatitis B virus (HBV) infection.
GILD: 91.86 (-0.11)
Five Prime Therapeutics Carves Out Tighter Base
at Investor's Business Daily - Wed Mar 30, 5:39PM CDT
Around the turn of the millennium, the Human Genome Project, with all its potential therapies, was a big factor of huge moves in biotech stocks. But what about the extracellular proteome, or the immunome? Five Prime Therapeutics (FPRX) has a library...
BIIB: 260.32 (+6.14), GILD: 91.86 (-0.11), BMY: 63.88 (+0.44), CELG: 100.09 (+1.29), FPRX: 40.63 (+0.79)
Global HCV Market: Gilead Sciences, AbbVie, J&J and Bristol-Myers Squibb Featured in 2016 Hepatitis C Virus Edition Report
PR Newswire Europe - Wed Mar 30, 11:45AM CDT
PUNE, India, March 30, 2016 /PRNewswire/ --
GILD: 91.86 (-0.11)
3 Biotech Stocks That Make the Grade for Investors
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 10:26AM CDT
The happening and volatile biotech sector continues to intrigue investors.
GILD: 91.86 (-0.11), SHPG: 171.90 (+3.40), HZNP: 16.57 (+0.56), AMGN: 149.93 (+0.45), AMAG: 23.40 (+1.28), BXLT: 40.40 (+0.25)
4 Value Stocks to Buy Now
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:43AM CDT
U.S. stock markets have been choppy this year, thanks to gyrations in oil price movements. This volatility makes investing in value stocks more appealing.
HCA: 78.05 (-0.05), JNJ: 108.20 (-0.78), GILD: 91.86 (-0.11), TGT: 82.28 (-1.32)
AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
PR Newswire - Tue Mar 29, 3:00PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the appointment of Howard B. Rosen as the Chief Executive Officer of AcelRx, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015. Mr. Rosen is an experienced and technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences, Inc. and ALZA Corporation. More recently he was interim CEO of Pearl Therapeutics which was subsequently acquired by Astra Zeneca for up to $1.15 billion in 2013. Mr. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra, Ltd. and two private biopharmaceutical companies.
ACRX: 3.08 (+0.01), GILD: 91.86 (-0.11), ADHD: 3.79 (+0.17)
The Zacks Analyst Blog Highlights: Accenture, Broadcom, Gilead Sciences, ULTA Salon, Cosmetics & Fragrance, and NetEase
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Accenture, Broadcom, Gilead Sciences, ULTA Salon, Cosmetics & Fragrance, and NetEase
NTES: 143.58 (+0.95), GILD: 91.86 (-0.11), ULTA: 193.74 (-0.37), ACN: 115.40 (+0.03), AVGO: 154.50 (-2.43)
Pandora and Noble Energy sink, Time Warner and Avon rise
AP - Mon Mar 28, 3:25PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq stock market:
NBL: 31.41 (+0.63), AVP: 4.81 (+0.11), CALM: 51.91 (+0.40), GILD: 91.86 (-0.11), P: 8.95 (-0.55), FINL: 21.10 (-0.24), HOT: 83.43 (-0.23), TWX: 72.55 (+0.39)
Buy These 5 Large Caps for Incredible ROI Potential
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 2:49PM CDT
Is EPS really a true measure of profits? Let us show you a much better gauge of a company's profitability - Return on Invested Capital.
NTES: 143.58 (+0.95), GILD: 91.86 (-0.11), WMT: 68.49 (-0.31), ULTA: 193.74 (-0.37), ACN: 115.40 (+0.03), AVGO: 154.50 (-2.43)
One Reason Why Gilead (GILD) Stock Is Advancing Today
at The Street - Mon Mar 28, 12:17PM CDT
Gilead (GILD) stock is higher in afternoon trading on Monday as its hepatitis C franchise 'proves durable in the face of increased competition,' according to Leerink.
GILD: 91.86 (-0.11)
After Yesterday's Rally of 2.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 28, 11:50AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.94 to a high of $94.31. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $93.96 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 91.86 (-0.11)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.05%
Comtex SmarTrend(R) - Mon Mar 28, 11:48AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.94 to a high of $94.31. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $93.96 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 91.86 (-0.11)
Bullish Gilead Trade Sets Up After Patent Verdict
at The Street - Mon Mar 28, 11:35AM CDT
Following a brief selloff on Hep-C drug dispute outcome, GILD looks interesting on the upside.
GILD: 91.86 (-0.11), MRK: 52.91 (-0.31)
Gilead to Pay $200 Million to Merck for HCV Patent Dispute
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 9:30AM CDT
Gilead Sciences (GILD) was ordered by a jury to pay $200 million to Merck for the damages related to a patent infringement involving hepatitis C virus drugs.
GILD: 91.86 (-0.11), MRK: 52.91 (-0.31), IONS: 40.50 (+1.87)
Gilead Sciences (GILD) Breaks Through Resistance at $92.95
Comtex SmarTrend(R) - Mon Mar 28, 9:09AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $91.19 and have already reached the first level of resistance at $92.95. Should the shares continue to rise, the resistance pivots of $94.57 and $97.95 will be of interest.
GILD: 91.86 (-0.11)
Gilead Sciences (GILD) Stock Lifted by Leerink's Confidence
at The Street - Thu Mar 31, 2:08PM CDT
It appears that Gilead Sciences (GILD) is continuing to dominate in hepatitis C, Leerink analysts said.
GILD: 91.86 (-0.11)
Pfizer Tops List of Best Biopharmaceutical Brands
at The Street - Thu Mar 31, 1:09PM CDT
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top 10 biopharmaceutical brands.
JNJ: 108.20 (-0.78), GILD: 91.86 (-0.11), AZN: 28.16 (-0.16), MRK: 52.91 (-0.31), PFE: 29.64 (-0.43), AMGN: 149.93 (+0.45), GSK: 40.55 (-0.15), NVS: 72.44 (-0.11)
5 Large Cap Stocks with P/Es Below 15: A Must Buy?
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 8:37AM CDT
Large Cap Stocks with P/Es below 15.
ZBH: 106.63 (-0.07), GILD: 91.86 (-0.11), XRX: 11.16 (+0.33), KORS: 56.96 (+0.09), HPE: 17.73 (-0.16)
Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection
BusinessWire - Thu Mar 31, 1:02AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has submitted a New Drug Application (NDA) to Japan's Pharmaceutical and Medical Devices Agency (PMDA) for tenofovir alafenamide (TAF) 25 mg, an investigational once-daily treatment for adults with chronic hepatitis B virus (HBV) infection.
GILD: 91.86 (-0.11)
Five Prime Therapeutics Carves Out Tighter Base
at Investor's Business Daily - Wed Mar 30, 5:39PM CDT
Around the turn of the millennium, the Human Genome Project, with all its potential therapies, was a big factor of huge moves in biotech stocks. But what about the extracellular proteome, or the immunome? Five Prime Therapeutics (FPRX) has a library...
BIIB: 260.32 (+6.14), GILD: 91.86 (-0.11), BMY: 63.88 (+0.44), CELG: 100.09 (+1.29), FPRX: 40.63 (+0.79)
Global HCV Market: Gilead Sciences, AbbVie, J&J and Bristol-Myers Squibb Featured in 2016 Hepatitis C Virus Edition Report
PR Newswire Europe - Wed Mar 30, 11:45AM CDT
PUNE, India, March 30, 2016 /PRNewswire/ --
GILD: 91.86 (-0.11)
3 Biotech Stocks That Make the Grade for Investors
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 10:26AM CDT
The happening and volatile biotech sector continues to intrigue investors.
GILD: 91.86 (-0.11), SHPG: 171.90 (+3.40), HZNP: 16.57 (+0.56), AMGN: 149.93 (+0.45), AMAG: 23.40 (+1.28), BXLT: 40.40 (+0.25)
4 Value Stocks to Buy Now
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:43AM CDT
U.S. stock markets have been choppy this year, thanks to gyrations in oil price movements. This volatility makes investing in value stocks more appealing.
HCA: 78.05 (-0.05), JNJ: 108.20 (-0.78), GILD: 91.86 (-0.11), TGT: 82.28 (-1.32)
AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
PR Newswire - Tue Mar 29, 3:00PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the appointment of Howard B. Rosen as the Chief Executive Officer of AcelRx, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015. Mr. Rosen is an experienced and technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences, Inc. and ALZA Corporation. More recently he was interim CEO of Pearl Therapeutics which was subsequently acquired by Astra Zeneca for up to $1.15 billion in 2013. Mr. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra, Ltd. and two private biopharmaceutical companies.
ACRX: 3.08 (+0.01), GILD: 91.86 (-0.11), ADHD: 3.79 (+0.17)
The Zacks Analyst Blog Highlights: Accenture, Broadcom, Gilead Sciences, ULTA Salon, Cosmetics & Fragrance, and NetEase
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Accenture, Broadcom, Gilead Sciences, ULTA Salon, Cosmetics & Fragrance, and NetEase
NTES: 143.58 (+0.95), GILD: 91.86 (-0.11), ULTA: 193.74 (-0.37), ACN: 115.40 (+0.03), AVGO: 154.50 (-2.43)
Pandora and Noble Energy sink, Time Warner and Avon rise
AP - Mon Mar 28, 3:25PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq stock market:
NBL: 31.41 (+0.63), AVP: 4.81 (+0.11), CALM: 51.91 (+0.40), GILD: 91.86 (-0.11), P: 8.95 (-0.55), FINL: 21.10 (-0.24), HOT: 83.43 (-0.23), TWX: 72.55 (+0.39)
Buy These 5 Large Caps for Incredible ROI Potential
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 2:49PM CDT
Is EPS really a true measure of profits? Let us show you a much better gauge of a company's profitability - Return on Invested Capital.
NTES: 143.58 (+0.95), GILD: 91.86 (-0.11), WMT: 68.49 (-0.31), ULTA: 193.74 (-0.37), ACN: 115.40 (+0.03), AVGO: 154.50 (-2.43)
One Reason Why Gilead (GILD) Stock Is Advancing Today
at The Street - Mon Mar 28, 12:17PM CDT
Gilead (GILD) stock is higher in afternoon trading on Monday as its hepatitis C franchise 'proves durable in the face of increased competition,' according to Leerink.
GILD: 91.86 (-0.11)
After Yesterday's Rally of 2.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 28, 11:50AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.94 to a high of $94.31. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $93.96 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 91.86 (-0.11)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.05%
Comtex SmarTrend(R) - Mon Mar 28, 11:48AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.94 to a high of $94.31. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $93.96 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 91.86 (-0.11)
Bullish Gilead Trade Sets Up After Patent Verdict
at The Street - Mon Mar 28, 11:35AM CDT
Following a brief selloff on Hep-C drug dispute outcome, GILD looks interesting on the upside.
GILD: 91.86 (-0.11), MRK: 52.91 (-0.31)
Gilead to Pay $200 Million to Merck for HCV Patent Dispute
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 9:30AM CDT
Gilead Sciences (GILD) was ordered by a jury to pay $200 million to Merck for the damages related to a patent infringement involving hepatitis C virus drugs.
GILD: 91.86 (-0.11), MRK: 52.91 (-0.31), IONS: 40.50 (+1.87)
Gilead Sciences (GILD) Breaks Through Resistance at $92.95
Comtex SmarTrend(R) - Mon Mar 28, 9:09AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $91.19 and have already reached the first level of resistance at $92.95. Should the shares continue to rise, the resistance pivots of $94.57 and $97.95 will be of interest.
GILD: 91.86 (-0.11)
